

Highlights from the Week of August 11-18, 2025



The landmark FDA approval of BRINSUPRI (brensocatic) becomes first-ever treatment for non-cystic fibrosis bronchiectasis

(FDA Approval)



Valneva's chikungunya vaccine receives an updated FDA label; the clinical hold has been lifted for the older adult population

(FDA, Clinical hold)



Superluminal Medicines and Eli Lilly partnered to develop small molecule drugs for cardiometabolic diseases and obesity

(Partnership)

Highlights from the Week of August 11-18, 2025



FDA expands Novo Nordisk's WEGOVY label to treat MASH-related liver fibrosis in adults

(FDA, Label Expansion)



Precigen's PAPZIMEOS receives full FDA approval as the first-ever therapy for recurrent respiratory papillomatosis in adults

(FDA Approval)



FDA grants Fast Track designation to NRx Pharma's NRX-100 for treating suicidal ideation in depression

(FDA, Fast Track Designation)

Highlights from the Week of August 11-18, 2025



GC Biopharma partners with the Thai Red Cross to advance plasma-derived therapies

(Collaboration)



FDA approves Tonix Pharmaceuticals' TONMYA as a new treatment for fibromyalgia

(FDA Approval)



FDA grants Fast Track status to Halda Therapeutics' HLD-0915 for metastatic castration-resistant prostate cancer

(FDA, Fast Track Designation)